#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

Peter Attia

Apr 13, 2026

Episode description

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];
What peptides are: basic definitions, biological roles, and therapeutic foundati

Mindsip insights from this episode:

Explore popular gray market peptides in biohacking

The most popular and frequently asked-about peptides in the biohacking space are SS-31, Melanotan 2, CJC-1295, and BPC-157.

#biohacking

#peptides

Classify peptides into four distinct categories

Peptides can be categorized into four buckets: those with no compelling case, those abandoned by pharma, those with off-label potential, and those that are essentially stolen versions of FDA-approved drugs.

#peptides

Distinguish between FDA-approved peptides and biohacking compounds

The word "peptide" has two meanings: FDA-approved therapeutics like insulin in medicine, and unregulated compounds for longevity or healing in the biohacking world.

#biohacking

#peptides

Ask five key questions before using peptides or drugs

Before taking any peptide or drug, you should ask five key questions: is there a viable mechanism, what are the effects in humans, what is the safety profile, what is the risk/benefit, and are there approved alternatives?.

#peptides

#safety

Question drugs and supplements lacking known mechanisms of action

You should be very skeptical of any drug or supplement without a known mechanism of action, as less than 3% of all FDA-approved drugs fall into this category.

#supplement

Address gray market loophole in peptide sales for human use

Many popular peptides are sold through a gray market loophole where they are labeled for "research use only" to avoid regulations, despite being intended for human use.

#peptides

#risk

Peter Attia

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy